CD274 and non-small cell lung carcinoma: This led to the approval of atezolizumab as adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II–IIIA NSCLC with PD-L1 expression of 1% or more, and the approval of Ventana SP263 as the companion diagnostic.